Ovid Therapeutics (OVID) EBIT Margin (2020 - 2025)
Ovid Therapeutics (OVID) posted EBIT Margin of 1712.12% for Q4 2025, up 81.95% on a QoQ basis from 9487.12% in Q3 2025, and up 1239578.0% year-over-year from N/an in Q4 2024.
Ovid Therapeutics (OVID) EBIT Margin (2020 - 2025) Analysis & Trends
Ovid Therapeutics' EBIT Margin history runs 6 years deep, the most recent figure standing at 1712.12% for Q4 2025.
- Quarterly EBIT Margin rose 1239578.0% year-over-year to 1712.12% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 670.25% (up 973395.0% YoY) and the FY2025 annual result came in at 585.2%, up 1034854.0% from the prior year.
- EBIT Margin was 1712.12% for Q4 2025 at Ovid Therapeutics, up from 9487.12% in the prior quarter.
- Across five years, EBIT Margin topped out at 84.73% in Q1 2021 and bottomed at 115329.27% in Q3 2022.
- A 5-year average of 17160.75% and a median of 11402.01% in 2023 frame the typical range for EBIT Margin.
- Peak annual rise in EBIT Margin reached 10429349 bps in 2023, while the deepest fall reached 2143817 bps in 2023.
- Ovid Therapeutics' EBIT Margin stood at 84.73% in 2021, then slumped by 31144 bps to 26302.75% in 2022, then soared by 51 bps to 12808.45% in 2023, then retreated by 10 bps to 14107.89% in 2024, then soared by 88 bps to 1712.12% in 2025.
- Business Quant data shows OVID's EBIT Margin at 1712.12% in Q4 2025, 9487.12% in Q3 2025, and 80.88% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 973.81 Bn | 973.81 Bn | - | - |
| 4 | BeOne Medicines | 471.51 Bn | 466.72 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.70 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | 31.68% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 23.02% |
| 10 | Ovid Therapeutics | 119.41 Mn | -36.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,712.12% |
| Sep 30, 2025 | -9,487.12% |
| Jun 30, 2025 | -80.88% |
| Mar 31, 2025 | -9,653.85% |
| Dec 31, 2024 | -14,107.89% |
| Sep 30, 2024 | -7,645.09% |
| Jun 30, 2024 | -12,140.24% |
| Mar 31, 2024 | -11,768.24% |
| Dec 31, 2023 | -12,808.45% |
| Sep 30, 2023 | -11,035.78% |
| Jun 30, 2023 | -18,896.00% |
| Mar 31, 2023 | -22,563.64% |
| Dec 31, 2022 | -26,302.75% |
| Sep 30, 2022 | -115,329.27% |
| Mar 31, 2022 | -1,125.47% |
| Mar 31, 2021 | 84.73% |
| Dec 31, 2020 | -378.58% |
| Sep 30, 2020 | -237.25% |